MELISA Institute integrates diverse areas of human life sciences including basic sciences, epidemiology, and clinical medicine, striving for the development of health solutions for people through research, with a special focus on maternal and fetal health, human reproduction, and women’s health.


Our institution’s core capabilities include advanced research in proteogenomics and the development and manufacturing of medical products with diagnostic or therapeutic applications.

One of our most important projects is the study of the embyo-mother cross-talk, through a bidirectional cohort, we are researching the proteomic and transcriptomic markers of ultra-early pregnancy, from the moment of ovulation to implantation. The big difference in our approach is the study of this process in vivo. In this way, we can know the mother-embryonic dialogue to find ultra-early markers of pregnancy and embryonic health.


In addition, MELISA Institute is interested in investigating social, economical, and biological determinants of women's health at the population level to help develop evidence-based politics to improve her lives.

The MELISA Institute is researching to understand the complex biological process of pregnancy from the moment of conception to implantation.

A randomized Clinical Trial to prevent Covid-19

MELISA Institute’s research aims for chemoprophylaxis against Covid-19 through the use of Previfenon®, preventing an effective incubation and enhancing systemic immunity.



Meet our Core Facility and find the services we provide.

Thank you for your interest in our investigations. If you have questions about our services, write to us through the following form:

Dalcahue 1120, suite 103, San Pedro de la Paz - Bio Bio, Chile | +56 41 246 7242